Quantcast
Last updated on April 17, 2014 at 12:01 EDT

Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis(TM) Immunotherapy at Needham & Company 10th Annual Healthcare Conference and Leerink Swann Cancer Roundtable Conference

April 5, 2011

DURHAM, N.C., April 5, 2011 /PRNewswire/ — Argos Therapeutics today announced that Jeff Abbey, the company’s president and chief executive officer, will present a corporate overview and the next steps in the clinical development of Argos’ Arcelis(TM) immunotherapy at the Needham & Company 10th Annual Healthcare Conference at 1:20 p.m. EDT on Wednesday, April 6, at The New York Palace Hotel. Mr. Abbey will also participate in a cancer immunotherapy panel at 8 a.m. EDT, as well as present a corporate overview at 4:10 p.m. EDT at the Leerink Swann Cancer Roundtable Conference on Thursday, April 7, at the Roosevelt Hotel in New York.

Argos is in the process of securing funding to begin a Phase 3 trial in renal cell carcinoma (RCC) with its Arcelis immunotherapy, AGS-003, in mid-2011. The company has presented favorable progression-free survival and safety results from an ongoing Phase 2 trial for AGS-003 in combination with sunitinib. Argos’ Arcelis HIV program, AGS-004, is also currently being tested in a double-blind, placebo controlled, randomized Phase 2b study co-funded by the NIH to further demonstrate that it is a feasible treatment option for HIV-1 infected patients. In addition, Argos has initiated dosing of patients in a Phase 1 clinical trial of its monoclonal antibody-based therapy, AGS-009, for the treatment of systemic lupus erythematosus (SLE).

About the Arcelis(TM) Technology

Arcelis is Argos’ proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient’s own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient’s disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA (“mRNA”) isolated from the patient’s disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient’s specific disease.

About Argos Therapeutics, Inc.

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com

Contacts:

David Schull or Andreas Marathovouniotis
Russo Partners LLC
(212) 845-4271 or (212) 845-4235
david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.com

Jeff Abbey
Argos Therapeutics
(919) 287-6308
jabbey@argostherapeutics.com

SOURCE Argos Therapeutics, Inc.


Source: newswire